Actively Recruiting
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
Led by Y. Michael Shim, MD · Updated on 2026-03-17
80
Participants Needed
2
Research Sites
419 weeks
Total Duration
On this page
Sponsors
Y
Y. Michael Shim, MD
Lead Sponsor
D
Duke University
Collaborating Sponsor
AI-Summary
What this Trial Is About
A two-center, longitudinal assessment of 40 electronic cigarette users and 40 healthy controls at the initial visit and a follow-up visit 12 months later. This study will determine the impact of electronic cigarette use on pulmonary gas exchange capacity and then corroborate the Hyperpolarized Xenon MRI (HXeMRI) results with the cardiopulmonary stress test at the initial visit and a follow-up visit 12 months later.
CONDITIONS
Official Title
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages between 18 and 35 years old.
- At their baseline health.
- Ability to understand a written informed consent form and comply with the study requirements.
- Exclusive long-term electronic cigarette use for more than six months, at least three days per week.
- Use of "closed-container" or "pre-packaged" electronic cigarette juices containing nicotine.
- Healthy subjects must have normal baseline lung function tests; e-cigarette users may have normal or abnormal spirometry with FEV1/FVC between 26-70.
You will not qualify if you...
- History of any other lung disease.
- History of brain diseases including stroke and dementia, end-stage liver disease, coronary artery disease, or renal failure.
- Acute infection within the previous 6 weeks.
- Pregnancy or possibility of pregnancy.
- Anemia.
- Inability to undergo pulmonary function testing, cardiopulmonary exercise testing, or MRI.
- Prior cigarette smoking of more than one pack-year within six months before enrollment.
- Use of non-closed container, custom-made electronic cigarette juice, or inability to access closed-container juices for chemical analysis.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Duke University
Durham, North Carolina, United States, 27705
Actively Recruiting
2
University of Virginia
Charlottesville, Virginia, United States, 22908
Actively Recruiting
Research Team
R
Roselove Asare, MA
CONTACT
C
Caleigh Smith, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here